Search Results 561-570 of 13934 for Assay

1. Cardiovascular Medicine - Clinical trials

   ... assay. International Triadin Knockout Syndrome Registry. Rochester, Minn. The aim of this study is to determine the worldwide prevalence of Triadin Knockout ...

2. Precision medicine for breast cancer - Doctors & Departments - Mayo Clinic

   Classification of BRCA2 variants of uncertain significance (VUS) using an ACMG/AMP model incorporating a homology-directed repair (HDR) functional assay.

3. Precision medicine for breast cancer - Doctors & Departments - Mayo Clinic

   Classification of BRCA2 variants of uncertain significance (VUS) using an ACMG/AMP model incorporating a homology-directed repair (HDR) functional assay.

4. Precision medicine for breast cancer - Doctors & Departments - Mayo Clinic

   Classification of BRCA2 variants of uncertain significance (VUS) using an ACMG/AMP model incorporating a homology-directed repair (HDR) functional assay.

5. Mayo Clinic joins Illumina, Warburg Pincus, and Sutter Hill Ventures to form Helix to Accelerate Consumer Adoption of Genomics

   ... assay, laboratory, or database infrastructure. “Genomics is reaching an inflection point in cost, volumes, and knowledge, creating a significant opportunity ...

6. Toxicology and Pharmacology Shared Resource - Department of Molecular Medicine - Mayo Clinic Research

   ... assays and preclinical studies to support investigators involved in the clinical translation of virus, gene and cell therapies from bench to clinic. The ...

7. Clinical trials - Mayo Clinic Children's

   This will be accomplished by utilizing the the immunoSEQ Human T-cell Receptor Beta (hsTCB) Assay (Adaptive Biothechnologies) and the publicly available ...

8. An inside look at the state-of-the-art supports enabling invention - Mayo Clinic News Network

   ... assays come to life. “Nationally ... For instance, when the bacteriology laboratory recently developed a broad-range 16s rRNA bacterial detection assay ...

9. Find clinical trials - Oncology (Medical)

   ... assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients ...

10. A Phase III, Randomised Study Of Adjuvant Dato-DXd In Combination With Rilvegostomig Or Rilvegostomig Monotherapy Versus Standard Of Care, Following Complete Tumour Resection, In Participants With Stage I Adenocarcinoma NSCLC Who Are CtDNA-positive Or Have High-risk Pathological Features - Mayo Clinic

    ... assay, or have at least one high-risk pathological feature. Participation eligibility. Participant eligibility includes age, gender, type and stage of ...